key: cord-1004070-6saqx066
authors: Innes, Hamish; Buch, Stephan; Barnes, Eleanor; Hampe, Jochen; Marjot, Thomas; Stickel, Felix
title: The rs738409 G allele in PNPLA3 is associated with a reduced risk of COVID-19 mortality and hospitalisation.
date: 2021-02-27
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.02.059
sha: 33d8e8e16e27c609e27599adbd6807231dda2150
doc_id: 1004070
cord_uid: 6saqx066

nan

FUNDING: HI is a Medical Research Foundation Viral Hepatitis Fellow. TM has received a registry grant from European Association for Study of the Liver (EASL) (2020RG03) and is supported by the

Investigator. This work was also, in part, supported by the Swiss National Science Foundation (SNF no. 310030_169196).

This research has been conducted using the United Kingdom (UK) Biobank Resource (application number: 8764). We also want to acknowledge the participants and investigators of the FinnGen study There are no conflicts of interest to declare. 

The natural history of SARS-CoV-2 infection is highly variable, ranging from asymptomatic infection on one hand, to pneumonia, septic shock, multiple organ failure and death on the other. [1] The physiological pathways that influence prognosis following infection are still incompletely understood; this represents a key barrier to optimal management. The rs738409 G variant in patatin-like phospholipase domain containing 3 (PNPLA3) is a prominent genetic risk factor for steatosis, cirrhosis and hepatocellular carcinoma. [2] For two reasons, we hypothesised that rs738409 G may also affect COVID-19 severity. Firstly, rs738409 G is associated with retinoid storage levels in liver mesenchymal cells [3] , which may have bearing on the ability to mount an effective immune response following viral infection [4] . Secondly, previous data suggest the rs738409 G increases cellular abundance of omega-3 polyunsaturated fatty acids (PUFAs) such as alpha linolenic acid [5] , which may modulate inflammatory processes levels during infections.

Our goal was to test a possible association of rs738409 G in PNPLA3 with outcomes of COVID-19 using data from the United Kingdom Biobank (UKB) study.

Our hypothesis was tested in UKB, a population-based cohort of ~500,000 middle-aged individuals in the UK. Latterly, data on participants testing positive for SARS-CoV-2 in England after 16 March 2020 have been released.

All UKB unrelated participants with: a) a positive PCR test result for SARs-CoV-2 between 16 th March 2020 and 15 th August 2020, and b) data available for the PNPLA3:rs738409 genotype were analyzed.

Primary endpoints in this study were: a) hospital admission for COVID-19; and b) death from COVID-19.

Logistic regression was used to assess the association between rs738409 G allele and each endpoint under additive and recessive genetic models. All models were adjusted for potential confounding factors.

We performed sensitivity analyses to check assumptions. First, we tested whether the association between rs738409 G and each outcome changed when individuals with liver disease were excluded.

We also assessed if the association varied according to ethnicity, coronary artery disease (CAD) and obesity, age and liver disease. Third, we determined the rs738409 G association with two specific types of COVID-19 hospitalisation; namely: i) hospital admission for COVID-19 with pneumonia recorded; and ii) hospital admission for COVID-19 entailing advanced respiratory support. Fourth, we calculated the association between rs738409 G and prevalent liver disease to ensure concordance with previous research [2] .

Further information, including detailed covariate and outcome definitions, is provided in the supplementary methods.

We meta-analysed the association between rs738409 G and COVID-19 morbidity from three studies/sources comparing patients with COVID-19 morbidity to SARS-CoV-2 positive patients with no/minimal morbidity. These data sources were: a) The FinnGen biobank; b) Geisinger Health Study;

3) Data on COVID-19 patients hospitalised in Palermo, Italy. [6] 

The primary analysis included 1585 UKB participants. Mean age was 67.9 years (sd:9.1), 52.7% were male, and three-quarter were White British (78.1%). The rs738409 G allele frequency was 20.9% (Table S1 ). The number of patients with a COVID-19 hospital admission, a COVID-19 admission with pneumonia, and a COVID-19 admission requiring advanced respiratory support was 759 (47.9%), 450(28.4%) and 76(4.8%), respectively. Approximately one-sixth of the sample died from COVID-19 (16.9%; n=267).

The rs738409 G allele was independently associated with a reduced risk of COVID-19 hospitalisation and mortality (Figure 1 ). On average, each additional G allele carried was associated with a 21% In meta-analysis of three independent data sources, rs738409 G showed a trend for association with a reduced risk of COVID-19 hospitalisation/severe disease versus mild disease; but the result did not reach statistical significance (additive OR: 0.83: 95%CI: 0.66-1.05; P=0.12; P heterogeneity=0.68); see Figure 1 .

J o u r n a l P r e -p r o o f These data show a lower risk of COVID-19 hospitalisation and death in carriers of the rs738409 G allele in PNPLA3, which is athwart to its risk-increasing effect on liver disease (Figure 1 ). However, although this association was robust in the UKB study against a broad set of COVID-19 related endpoints and with adjustment for a comprehensive set of covariates, it was only moderately supported by independent validation data (i.e. the effect was directionally concordant but not statistically significant in the validation data). Further data from larger well-defined cohorts including data on mortality are therefore required to verify the association of rs738409 G with COVID-19 sequelae. Functionally, this association could reflect the influence of lipid metabolism on the immune response to COVID-19. E.g., retinoids are stored as retinyl esters in hepatic mesenchymal cells and also in adipose tissue where PNPLA3 is expressed. When required, retinoids are mobilised to extrahepatic tissues where they can stimulate interferon type 1 production as a potent cytokine response to viral infections. [4] PNPLA3 has retinyl-palmitate lipase activity which stimulates release of retinol into the systemic circulation. [7] Accordingly, individuals with the I148M loss-of-function variant (encoded by rs738409 G) exhibit lower circulating retinoid levels [7] and increased retinoid storage levels in the liver [3] . In contrast, some risk factors for severe COVID-19 (e.g. obesity and liver disease [8] ) are associated with diminished retinoid levels and/or impaired retinoid signalling, which may limit retinoid availability during infection. This finding may also reflect a lower omega-6 to omega-3-PUFA ratio in individuals with the rs738409 G allele, [5] which may temper inflammation, and safeguard against cytokine-storm-syndrome.

In summary, we report a putative association between PNPLA3:rs738409 and COVID-19 severity. In doing so, we provide an example of how pleiotropic effects of certain genetic risk loci affect disease endpoints differently. 

Figure 1. Association of rs738409 G allele with COVID-19 severity and prevalent liver disease